S&P Global Inc. vs Vertex Pharmaceuticals Incorporated
์๊ฐ์ ๋ฐ๋ฅธ ์๊ฐ์ด์ก ๋น๊ต
S&P Global Inc.
$130.2B
์์ #138
Vertex Pharmaceuticals Incorporated
$134.0B
์์ #133
์๊ฐ์ ๋ฐ๋ฅธ ์๊ฐ์ด์ก
์ฃผ์ ์๊ฐ
- S&P Global Inc.์ด(๊ฐ) 1998๋ ๊น์ง Vertex Pharmaceuticals Incorporated์(๋ฅผ) ์ถ์ํ์ต๋๋ค
- Vertex Pharmaceuticals Incorporated์ด(๊ฐ) 2000๋ ๊น์ง S&P Global Inc.์(๋ฅผ) ์ถ์ํ์ต๋๋ค
- S&P Global Inc.์ด(๊ฐ) 2002๋ ๊น์ง Vertex Pharmaceuticals Incorporated์(๋ฅผ) ์ถ์ํ์ต๋๋ค
- Vertex Pharmaceuticals Incorporated์ด(๊ฐ) 2008๋ ๊น์ง S&P Global Inc.์(๋ฅผ) ์ถ์ํ์ต๋๋ค
- S&P Global Inc.์ด(๊ฐ) 2011๋ ๊น์ง Vertex Pharmaceuticals Incorporated์(๋ฅผ) ์ถ์ํ์ต๋๋ค
- Vertex Pharmaceuticals Incorporated์ด(๊ฐ) 2014๋ ๊น์ง S&P Global Inc.์(๋ฅผ) ์ถ์ํ์ต๋๋ค
- S&P Global Inc.์ด(๊ฐ) 2016๋ ๊น์ง Vertex Pharmaceuticals Incorporated์(๋ฅผ) ์ถ์ํ์ต๋๋ค
- Vertex Pharmaceuticals Incorporated์ด(๊ฐ) 2026๋ ๊น์ง S&P Global Inc.์(๋ฅผ) ์ถ์ํ์ต๋๋ค
์ฐ๋๋ณ ๋น๊ต
| ์ฐ๋ | S&P Global Inc. | Vertex Pharmaceuticals Incorporated | ์ ๋ |
|---|---|---|---|
| 2026 | $130.2B | $134.0B | Vertex Pharmaceuticals Incorporated |
| 2025 | $154.0B | $115.1B | S&P Global Inc. |
| 2024 | $145.7B | $102.2B | S&P Global Inc. |
| 2023 | $127.8B | $103.3B | S&P Global Inc. |
| 2022 | $96.3B | $73.3B | S&P Global Inc. |
| 2021 | $134.4B | $55.7B | S&P Global Inc. |
| 2020 | $92.9B | $60.0B | S&P Global Inc. |
| 2019 | $76.5B | $55.6B | S&P Global Inc. |
| 2018 | $47.2B | $42.1B | S&P Global Inc. |
| 2017 | $46.5B | $38.0B | S&P Global Inc. |
| 2016 | $29.2B | $18.7B | S&P Global Inc. |
| 2015 | $26.4B | $31.9B | Vertex Pharmaceuticals Incorporated |
| 2014 | $23.5B | $30.2B | Vertex Pharmaceuticals Incorporated |
| 2013 | $20.4B | $18.9B | S&P Global Inc. |
| 2012 | $13.3B | $10.6B | S&P Global Inc. |
| 2011 | $10.7B | $8.4B | S&P Global Inc. |
| 2010 | $8.5B | $8.9B | Vertex Pharmaceuticals Incorporated |
| 2009 | $7.6B | $10.9B | Vertex Pharmaceuticals Incorporated |
| 2008 | $5.1B | $7.7B | Vertex Pharmaceuticals Incorporated |
| 2007 | $9.3B | $5.9B | S&P Global Inc. |
| 2006 | $14.3B | $9.5B | S&P Global Inc. |
| 2005 | $10.7B | $7.0B | S&P Global Inc. |
| 2004 | $9.4B | $2.7B | S&P Global Inc. |
| 2003 | $7.0B | $2.6B | S&P Global Inc. |
| 2002 | $6.0B | $4.0B | S&P Global Inc. |
| 2001 | $5.9B | $6.2B | Vertex Pharmaceuticals Incorporated |
| 2000 | $5.6B | $18.1B | Vertex Pharmaceuticals Incorporated |
| 1999 | $5.8B | $4.4B | S&P Global Inc. |
| 1998 | $4.7B | $3.8B | S&P Global Inc. |
| 1997 | $3.3B | $4.2B | Vertex Pharmaceuticals Incorporated |
| 1996 | $2.0B | $5.1B | Vertex Pharmaceuticals Incorporated |
| 1995 | $1.9B | $3.4B | Vertex Pharmaceuticals Incorporated |
| 1994 | $1.4B | $1.9B | Vertex Pharmaceuticals Incorporated |